Modern concepts of etiopathogenesis and approaches to the treatment of recurrent vulvovaginal candidiasis
- Authors: Rakhmatulina M.R.1
-
Affiliations:
- State Research Center of Dermatovenereology and Cosmetology
- Issue: Vol 99, No 4 (2023)
- Pages: 124-135
- Section: GUIDELINES FOR PRACTITIONERS
- URL: https://journals.rcsi.science/0042-4609/article/view/146545
- DOI: https://doi.org/10.25208/vdv11879
- ID: 146545
Cite item
Full Text
Abstract
Vulvovaginal candidiasis is a widespread infection caused by Candida. The disease affects 75–80% of women of reproductive age at least once during their lifetime, and 9–20% of them indicate the presence of three or more episodes of the disease during the year, which is classified as recurrent vulvovaginal candidiasis (RVVC). To date, the question of the causes of the formation of recurrent forms of the disease has not been definitively resolved, since RVVC is also observed in women who do not have known risk factors. Due to the fact that about 20–30% of patients with RVVC are healthy women without factors predisposing to its development, interindividual differences such as genetic predisposition and ethnicity, immune disorders, as well as the species diversity of Candida fungi and their antimycotic resistance may play a key role in the pathogenesis of idiopathic RVVC.
In the literature review, the main etiopathogenetic mechanisms of the disease development are presented, the role of immune and genetic factors of predisposition to the development of recurrent vulvovaginal candidiasis is evaluated, changes in the species structure of the pathogen in recent years are analyzed. Modern approaches to the treatment of the disease are described, taking into account the indicators of antimycotic resistance, and the analysis of RVVC therapy regimens according to domestic and foreign clinical recommendations is carried out. The possibilities of using sertaconazole in the treatment of the disease are considered, the results of studies of its efficacy and safety in patients with vulvovaginal candidiasis are presented.
Full Text
##article.viewOnOriginalSite##About the authors
Margarita R. Rakhmatulina
State Research Center of Dermatovenereology and Cosmetology
Author for correspondence.
Email: rahmatulina@cnikvi.ru
ORCID iD: 0000-0003-3039-7769
SPIN-code: 6222-8684
Scopus Author ID: 55312504700
ResearcherId: I-5449-2014
MD, Dr. Sci. (Med), Professor
Russian Federation, 3 bld. 6 Korolenko street, 107076 MoscowReferences
- Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369(9577):1961–1971. doi: 10.1016/S0140-6736(07)60917-9
- Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(11):e339–e347. doi: 10.1016/S1473-3099(18)30103-8
- Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2016;214(1):15–21. doi: 10.1016/j.ajog.2015.06.067
- Foxman B, Muraglia R, Dietz JP, Sobel JD, Wagner J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis. 2013;17(3):340–345. doi: 10.1097/LGT.0b013e318273e8cf
- Sobel JD. Genital candidiasis. Medicine. 2014;42(7):364–368. doi: 10.1016/j.mpmed.2014.04.006
- Spacek J, Jilek P, Buchta V, Forstl M, Hronek M, Holeckova M. The serum levels of calcium, magnesium, iron and zinc in patients with recurrent vulvovaginal candidosis during attack, remission and in healthy controls. Mycoses. 2005;48(6):391–395. doi: 10.1111/j.1439-0507.2005.01164.x
- Рахматулина М.Р., Малова И.О., Соколовский Е.В., Савичева А.М., Серов В.Н., Аполихина И.А. Федеральные клинические рекомендации по ведению больных урогенитальным кандидозом. Акушерство и гинекология. 2016;(4 Прил.):50–56 [Rahmatulina MR, Malova IO, Sokolovskij EV, Savicheva AM, Serov VN, Apolihina IA. Federal clinical guidelines for the management of patients with urogenital candidiasis. Akusherstvo i ginekologija. 2016;(4 Suppl):50–56. (In Russ.)]
- Зароченцева Н.В., Белая Ю.М. Проблема урогенитального кандидоза у женщин в современном мире. РМЖ. 2016;(15):976–979 [Zarochenсeva NV, Belaja JuM. The problem of urogenital candidiasis in women in the modern world. RMZh. 2016;(15):976–979. (In Russ.)]
- Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010;23(2):253–73. doi: 10.1128/CMR.00076-09
- Vulvovaginal candidiasis. Centers for Disease Control and Prevention; 2021. (Accessed July 14, 2023). https://www.cdc.gov/std/treatment-guidelines/candidiasis.htm
- Blostein F, Levin-Sparenberg E, Wagner J, Foxman B. Recurrent vulvovaginal candidiasis. Ann Epidemiol. 2017;27(9):575–582.e3. doi: 10.1016/j.annepidem.2017.08.010
- Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4680–4687. doi: 10.1073/pnas.1002611107
- Drell T, Lillsaar T, Tummeleht L, Simm J, Aaspõllu A, Väin E, et al. Characterization of the vaginal micro- and mycobiome in asymptomatic reproductive-age Estonian women. PLoS One. 2013;8(1):e54379. doi: 10.1371/journal.pone.0054379
- Parolin C, Marangoni A, Laghi L, Foschi C, Ñahui Palomino RA, Calonghi N, et al. Isolation of vaginal lactobacilli and characterization of anti-candida activity. PLoS One. 2015;10(6):e0131220. doi: 10.1371/journal.pone.0131220
- Jang SJ, Lee K, Kwon B, You HJ, Ko G. Vaginal lactobacilli inhibit growth and hyphae formation of Candida albicans. Sci Rep. 2019;9(1):8121. doi: 10.1038/s41598-019-44579-4
- Noverr MC, Huffnagle GB. Regulation of Candida albicans morphogenesis by fatty acid metabolites. Infect Immun. 2004;72(11):6206–6210. doi: 10.1128/IAI.72.11.6206-6210.2004
- Van Ende M, Wijnants S, Van Dijck P. Sugar Sensing and Signaling in Candida albicans and Candida glabrata. Front Microbiol. 2019;10:99. doi: 10.3389/fmicb.2019.00099
- Tarry W, Fisher M, Shen S, Mawhinney M. Candida albicans: the estrogen target for vaginal colonization. J Surg Res. 2005;129(2):278–282. doi: 10.1016/j.jss.2005.05.019
- Willems HME, Ahmed SS, Liu J, Xu Z, Peters BM. Vulvovaginal candidiasis: a current understanding and burning questions. J Fungi (Basel). 2020;6(1):27. doi: 10.3390/jof6010027
- Rosati D, Bruno M, Jaeger M, Ten Oever J, Netea MG. Recurrent vulvovaginal candidiasis: an immunological perspective. Microorganisms. 2020;8(2):144. doi: 10.3390/microorganisms8020144
- Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit Rev Microbiol. 2016;42(6):905–927. doi: 10.3109/1040841X.2015.1091805
- Mårdh PA, Rodrigues AG, Genç M, Novikova N, Martinez-de-Oliveira J, Guaschino S. Facts and myths on recurrent vulvovaginal candidosis — a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. Int J STD AIDS. 2002;13(8):522–539. doi: 10.1258/095646202760159639
- Neal CM, Martens MG. Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis. SAGE Open Med. 2022;10:20503121221115201. doi: 10.1177/20503121221115201
- Погосян Ш.М., Межевитинова Е.А., Донников А.Е., Прилепская В.Н., Бурменская О.В., Непша О.С., и др. Генетическая предрасположенность к рецидивирующему течению вульвовагинального кандидоза. Гинекология. 2017;19(4):20–25 [Pogosjan ShM, Mezhevitinova EA, Donnikov AE, Prilepskaja VN, Burmenskaja OV, Nepsha OS, et al. Genetic predisposition to a recurrent course of vulvovaginal candidiasis. Ginekologija. 2017;19(4):20–25. (In Russ.)] doi: 10.26442/2079-5696_19.4.20-25
- Hammad NM, El Badawy NE, Nasr AM, Ghramh HA, Al Kady LM. Mannose-binding lectin gene polymorphism and its association with susceptibility to recurrent vulvovaginal candidiasis. Biomed Res Int. 2018;2018:7648152. doi: 10.1155/2018/7648152
- Babula O, Lazdane G, Kroica J, Ledger WJ, Witkin SS. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin Infect Dis. 2003;37(5):733–737. doi: 10.1086/377234
- Liu F, Liao Q, Liu Z. Mannose-binding lectin and vulvovaginal candidiasis. Int J Gynaecol Obstet. 2006;92(1):43–47. doi: 10.1016/j.ijgo.2005.08.024
- Giraldo PC, Babula O, Gonçalves AK, Linhares IM, Amaral RL, Ledger WJ, et al. Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol. 2007;109(5):1123–1128. doi: 10.1097/01.AOG.0000260386.17555.a5
- Donders GG, Babula O, Bellen G, Linhares IM, Witkin SS. Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. BJOG. 2008;115(10):1225–1231. doi: 10.1111/j.1471-0528.2008.01830.x
- Plantinga TS, van der Velden WJ, Ferwerda B, van Spriel AB, Adema G, Feuth T, et al. Early stop polymorphism in human DECTIN-1 is associated with increased candida colonization in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2009;49(5):724–732. doi: 10.1086/604714
- Babula O, Lazdāne G, Kroica J, Linhares IM, Ledger WJ, Witkin SS. Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis. 2005;40(9):1258–1262. doi: 10.1086/429246
- Cetin M, Ocak S, Gungoren A, Hakverdi AU. Distribution of Candida species in women with vulvovaginal symptoms and their association with different ages and contraceptive methods. Scand J Infect Dis. 2007;39(6-7):584–588. doi: 10.1080/00365540601148491
- De Vos MM, Cuenca-Estrella M, Boekhout T, Theelen B, Matthijs N, Bauters T, et al. Vulvovaginal candidiasis in a Flemish patient population. Clin Microbiol Infect. 2005;11(12):1005–1011. doi: 10.1111/j.14690691.2005.01281.x
- Vermitsky JP, Self MJ, Chadwick SG, Trama JP, Adelson ME, Mordechai E, Gygax SE. Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection. J Clin Microbiol. 2008;46(4):1501–1503. doi: 10.1128/JCM.02485-07
- Holland J, Young ML, Lee O, C-A Chen S. Vulvovaginal carriage of yeasts other than Candida albicans. Sex Transm Infect. 2003;79(3):249–250. doi: 10.1136/sti.79.3.249
- Corsello S, Spinillo A, Osnengo G, Penna C, Guaschino S, Beltrame A, et al. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol. 2003;110(1):66–72. doi: 10.1016/S0301-2115(03)00096-4
- Linhares LM, Witkin SS, Miranda SD, Fonseca AM, Pinotti JA, Ledger WJ. Differentiation between women with vulvovaginal symptoms who are positive or negative for Candida species by culture. Infect Dis Obstet Gynecol. 2001;9(4):221–225. 37. doi: 10.1155/S1064744901000369
- Okungbowa FI, Isikhuemhen OS, Dede AP. The distribution frequency of Candida species in the genitourinary tract among symptomatic individuals in Nigerian cities. Rev Iberoam Micol. 2003;20(2):60–63.
- Amouri I, Sellami H, Borji N, Abbes S, Sellami A, Cheikhrouhou F, et al. Epidemiological survey of vulvovaginal candidosis in Sfax, Tunisia. Mycoses. 2011;54(5):e499–505. doi: 10.1111/j.1439-0507.2010.01965.x
- Sherry L, Kean R, McKloud E, O'Donnell LE, Metcalfe R, Jones BL, et al. Biofilms formed by isolates from recurrent vulvovaginal candidiasis patients are heterogeneous and insensitive to fluconazole. Antimicrob Agents Chemother. 2017;61(9):e01065-17. doi: 10.1128/AAC.01065-17
- Рахматулина М.Р., Тарасенко Э.Н. Частота выявления грибов рода Candida у пациентов с урогенитальным кандидозом и анализ показателей их антимикотической резистентности за десятилетний период (2010–2020 гг.). Акушерство и гинекология. 2020;(7):159–165 [Rahmatulina MR, Tarasenko EN. The detection rate of fungi of the Candida genus in patients with urogenital candidiasis and an analysis of the indicators of their antimycotic resistance over a ten-year period (2010–2020). Akusherstvo i ginekologija. 2020;(7):159–165. (In Russ.)] doi: 10.18565/aig.2020.7.159-165
- Antimicrobial resistance: global report on surveillance. Geneva: World Health Organization; 2014. 232 p. ISBN 978-92-4-156474-8
- Sobel JD, Sobel R. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert Opin Pharmacother. 2018;19(9):971–977. doi: 10.1080/14656566.2018.1476490
- Makanjuola O, Bongomin F, Fayemiwo SA. An Update on the roles of non-albicans Candida species in vulvovaginitis. J Fungi (Basel). 2018;4(4):121. doi: 10.3390/jof4040121
- Collins LM, Moore R, Sobel JD. Prognosis and long-term outcome of women with idiopathic recurrent vulvovaginal candidiasis caused by Candida albicans. J Low Genit Tract Dis. 2020;24(1):48–52. doi: 10.1097/LGT.0000000000000496
- Chen SC, Sorrell TC. Antifungal agents. Med J Aust. 2007;187(7):404–409. doi: 10.5694/j.1326-5377.2007.tb01313.x
- Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol. 2003;11(6):272–279. doi: 10.1016/s0966-842x(03)00117-3
- Martin Lopez JE. Candidiasis (vulvovaginal). BMJ Clin Evid. 2015;2015:0815.
- Nurbhai M, Grimshaw J, Watson M, Bond C, Mollison J, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev. 2007;(4):CD002845. doi: 10.1002/14651858.CD002845.pub2
- Watson MC, Grimshaw JM, Bond CM, Mollison J, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review. BJOG. 2002;109(1):85–95. doi: 10.1111/j.1471-0528.2002.01142.x
- Cooke G, Watson C, Deckx L, Pirotta M, Smith J, van Driel ML. Treatment for recurrent vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev. 2022;1(1):CD009151. doi: 10.1002/14651858.CD009151.pub2
- Sobel JD, Brooker D, Stein GE, Thomason JL, Wermeling DP, Bradley B, et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group. Am J Obstet Gynecol. 1995;172(4 Pt 1):1263–1268. doi: 10.1016/0002-9378(95)91490-0
- Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50. doi: 10.1093/cid/civ933
- Crouss T, Sobel JD, Smith K, Nyirjesy P. Long-term outcomes of women with recurrent vulvovaginal candidiasis after a course of maintenance antifungal therapy. J Low Genit Tract Dis. 2018;22(4):382–386. doi: 10.1097/LGT.0000000000000413
- Vaginitis in nonpregnant patients. ACOG Practice Bulletin. 2020;(215). (Accessed July 14, 2023). https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2020/01/vaginitis-in-nonpregnant-patients
- Sherrard J, Wilson J, Donders G, Mendling W, Jensen JS. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018;29(13):1258–1272. doi: 10.1177/0956462418785451
- Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351(9):876–883. doi: 10.1056/NEJMoa033114
- Donders G, Bellen G, Byttebier G, Verguts L, Hinoul P, Walckiers R, et al. Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol. 2008;199(6):613.e1-9. doi: 10.1016/j.ajog.2008.06.029
- Matheson A, Mazza D. Recurrent vulvovaginal candidiasis: A review of guideline recommendations. Aust N Z J Obstet Gynaecol. 2017;57(2):139–145. doi: 10.1111/ajo.12592
- Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol. 2012;120(6):1407–1414. doi: 10.1097/aog.0b013e31827307b2
- Mintz JD, Martens M. Prevalence of non-albicans Candida infections in women with recurrent vulvovaginal symptomatology. Adv Infect Dis. 2013;3(4):238–242. doi: 10.4236/aid.2013.34035
- Farr A, Effendy I, Frey Tirri B, Hof H, Mayser P, Petricevic L, et al. Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k). Mycoses. 2021;64(6):583–602. doi: 10.1111/myc.13248
- Урогенитальный кандидоз. Клинические рекомендации. М.; 2020. 26 с. [Urogenital'nyj kandidoz. Klinicheskie rekomendacii. (Urogenital candidiasis. Clinical recommendations.) Moscow; 2020. 20 p. (In Russ.)] (Accessed July 16, 2023). https://www.cnikvi.ru/docs/clinic_recs/klinicheskie-rekomendatsii-2019-2020
- Palacín C, Tarragó C, Ortiz JA. Sertaconazole: pharmacology of a gynecological antifungal agent. Int J Gynaecol Obstet. 2000;71(Suppl 1):S37–46. doi: 10.1016/s0020-7292(00)00351-9
- Carrillo-Muñoz AJ, Torres-Rodriguez JM. In-vitro antifungal activity of sertaconazole, econazole, and bifonazole against Candida spp. J Antimicrob Chemother. 1995;36(4):713–716. doi: 10.1093/jac/36.4.713
- Palacín C, Tarragó C, Agut J, Guglietta A. In vitro activity of sertaconazole, fluconazole, ketoconazole, fenticonazole, clotrimazole and itraconazole against pathogenic vaginal yeast isolates. Methods Find Exp Clin Pharmacol. 2001;23(2):61–64. doi: 10.1358/mf.2001.23.2.627926
- Quereux C, Gelas B, Chevallier T, Petit F, Micheletti MC. [Evaluation of the efficacity and speed of action of sertaconazole nitrate suppository and cream combined treatment for vulvovaginal candidiasis]. Gynecol Obstet Fertil. 2000;28(3):238–244.
- Dellenbach P, Thomas JL, Guerin V, Ochsenbein E, Contet-Audonneau N. Topical treatment of vaginal candidosis with sertaconazole and econazole sustained-release suppositories. Int J Gynaecol Obstet. 2000;71(Suppl 1):S47–S52. doi: 10.1016/s0020-7292(00)00348-9
- López-Olmos J, Lerma E, Parra I. Comparison of single dose fenticonazole versus sertaconazole as the treatment of vulvovaginal candidiasis: a prospective, multicentre study over one year. Clinica e Investigacion En Ginecologia y Obstetricia. 2003;30(1):10–17.
- Wang PH, Chao HT, Chen CL, Yuan CC. Single-dose sertaconazole vaginal tablet treatment of vulvovaginal candidiasis. J Chin Med Assoc. 2006;69(6):259–263. doi: 10.1016/S1726-4901(09)70253-9
- Azcona O, Torrent J, Vergés J, Márquez M, Albet C, Ortiz J, et al. Tolerance and kinetic behavior after single and repeated vaginal administration of sertaconazole cream and tablets in healthy volunteers. Eur J Pharmacol. 1999;183(3):1033. doi: 10.1016/0014-2999(90)92889-Q
- De Lunardo MC, Muzard G, Guerin V, Delance V, Thomas JL Caractéristiques pharmacocinétiques d'un nouvel antifongique imidazolé: le nitrate de sertaconazole. J Mycol Med. 1999;(9):137–142.
- Логутова Л.С., Гаспарян Н.Д., Горенкова О.С., Кручинина Е.В., Алимова Н.Г. Противорецидивный эффект различных антимикотических препаратов местного действия. Акушерство и гинекология. 2008;(3):53–56 [Logutova LS, Gasparjan ND, Gorenkova OS, Kruchinina EV, Alimova NG. Anti-relapse effect of various local antimycotic drugs. Akusherstvo i ginekologija 2008;(3):53–56 (In Russ.)].
- Palacín C, Tarragó C, Ortiz JA. Sertaconazole: pharmacology of a gynecological antifungal agent. Int J Gynaecol Obstet. 2000;71(Suppl 1):S37–46. doi: 10.1016/s0020-7292(00)00351-9
- Prats G, Mirelis B. Actividad antibacteriana in vitro de sertaconazol. Rev Esp Quimioter. 1995;8:325–326.
- Agut J, Tarrida N, Sacristán A, Ortiz JA. Antiinflammatory activity of topically applied sertaconazole nitrate. Methods Find Exp Clin Pharmacol. 1996;18(4):233–234.
- Серов В.Н. Проблема вульвовагинального кандидоза в гинекологической практике. РМЖ. 2014;(6):418–422 [Serov VN. The problem of vulvovaginal candidiasis in gynecological practice. RMZh. 2014;(6):418–422. (In Russ.)]
Supplementary files
